{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-027444","form_type":"8-K","ticker":"ALMS","cik":"0001847367","company_name":"ALUMIS INC.","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.268177+00:00","generated_at":"2026-05-24T05:59:54.122264+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alumis licenses ESK-001 to Kaken for Japan; $40M upfront/near-term plus $140M milestones","bullets":["Alumis receives $20M upfront and $20M co-development payments from Kaken in 2025-2026.","Kaken gets exclusive rights to develop/commercialize ESK-001 for dermatology in Japan, with options for rheumatology and GI.","Alumis retains rights outside Japan; Kaken contributes to global development costs.","Cash runway extended through Phase 3 ONWARD psoriasis topline data readout.","Tiered royalties on Japan net sales: low double-digits to twenties percent."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-027444","json":"https://secwatch.observer/filing/0001104659-25-027444.json","markdown":"https://secwatch.observer/filing/0001104659-25-027444.md","text":"https://secwatch.observer/filing/0001104659-25-027444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925027444/0001104659-25-027444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847367/000110465925027444/tm2510181d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:59:54.122264+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}